Guangdong Hybribio Biotech Co.,Ltd. (SZSE: 300639)
Health Care · Biotechnology · CN
CN¥6.18
-3.59% today · -7.9% 1Y
Guangdong Hybribio Biotech Co.,Ltd. (SZSE: 300639) operates in the Biotechnology industry within the Health Care sector. The company is valued at $576.98M and employs 1,990 people.
Over the last twelve months the share price has lost 7.9%, trading between 4.75 and 10.07.
Tweenvest scores Guangdong Hybribio Biotech Co.,Ltd. across four factors: quality 66/100, value 34/100, growth 33/100. Its strongest factor is quality.
300639 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $576.98M
- Revenue (TTM)
- $96.38M
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 0.42
- 52-week high
- CN¥10.07
- 52-week low
- CN¥4.75
- Avg volume (3M)
- —
- Shares outstanding
- 627.62M
- Employees
- 1,990
- Next earnings
- —
About Guangdong Hybribio Biotech Co.,Ltd.
Guangdong Hybribio Biotech Co., Ltd. engages in the research, development, production, and sale of nucleic acid molecular diagnostic products in China. It also provides on-site technical training and after-sales technical service support. The company was founded by Qiao Zhong Guan on June 13, 2003 and is headquartered in Chaozhou, China.
- ISIN
- CNE100002N51
- Founded
- 2003
- Listed since
- Apr 13, 2017
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.